Cost-effectiveness of eplerenone in patients with systolic heart failure and mild symptoms

July 11, 2014

Source: Heart online first

Follow this link for fulltext

Date of publication: July 2014

Publication type: Research

In a nutshell: Results from the EMPHASIS-HF trial (‘Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure’) were used to develop a simulation model estimating lifetime direct costs of prescribing eplerenone to patients with chronic systolic heart failure (HF). Eplerenone was regarded as cost-effective at a willingness-to-pay threshold of £20 000 per QALY (Quality-Adjusted Life Years).

Length of publication: 7 pages

Some important notes: Please contact your local NHS library if you cannot access the full text. Follow this link to find your local NHS library.


The cost effectiveness of ivabradine in the treatment of chronic heart failure

June 19, 2014

Source: Heart, 2014, 100 (13) p. 1031-6

Follow this link for fulltext

Date of publication: July 2014

Publication type: Journal article

In a nutshell: This economic evaluation assessed the cost-effectiveness of ivabradine from the perspective of the UK National Health Service, based on the results of the SHIfT trial. Ivabradine is expected to have a 95% chance of being cost-effective in the EU-licensed population using the current NICE cost-effectiveness threshold of £20,000 per QALY.

Length of publication: 6 pages

Some important notes: Please contact your local NHS library if you cannot access the full text. Follow this link to find your local NHS library.


The cost effectiveness of ivabradine in the treatment of chronic heart failure

March 17, 2014

Source: Heart Online First

Follow this link for fulltext

Date of publication: March 2014

Publication type: Journal article

In a nutshell: This economic evaluation suggests that use of the drug ivabradine for heart failure (HF) is cost-effective for patients with HF.

Length of publication: 6 pages

Some important notes: Please contact your local NHS library if you cannot access the full text. Follow this link to find your local NHS library.


Hypertension: evidence update March 2013

March 18, 2013

Source: National Institute for Health and Clinical Excellence

Follow this link for fulltext

Date of publication: March 2013

Publication type: Practice guidelines

In a nutshell: NICE has published an evidence update on hypertension, summarising a selection of new evidence published since the last literature search. Topics include the diagnosis of hypertension, antihypertensive drug treatment and patient education.

Length of publication: 27 pages

Some important notes: Please contact your local NHS library if you cannot access the full text. Follow this link to find your local NHS library.

Acknowledgement: NHS Evidence


Consultation on the draft document ‘Together for health – a cardiac delivery plan’

August 15, 2012

Source: Welsh Government

Follow this link for fulltext

Date of publication: August 2012

Publication type: Care plan

In a nutshell: Cardiac disease is the largest cause of death among the Welsh population. The Welsh Government has launched a draft strategy for a National Cardiac Delivery Plan, setting out its vision for Wales and what this entails for cardiac services in the NHS. The consultation is now open for comment, and will remain open until the 26th October 2012. Views from clinicians, NHS managers and service users are welcome.

Length of publication: 1 webpage

Some important notes: Please contact your local NHS library if you cannot access the full text. Follow this link to find your local NHS library.


Lay perspectives on hypertension and drug adherence

July 18, 2012

Source: BMJ, early online, 9th July 2012

Follow this link for fulltext

Date of publication: July 2012

Publication type: Systematic review

In a nutshell: This systematic review looked at 53 qualitative studies of patients with hypertension. The interviews highlighted patients’ beliefs and understanding of the causes and effects of hypertension and gave some explanation for their non-adherence to drug treatment. The authors concluded that clinicians need to understand better their patients’ concerns about drug side effects and experiences with symptoms.

Length of publication: 16 pages

Some important notes: Please contact your local NHS library if you cannot access the full text. Follow this link to find your local NHS library.


Four in one polypill halves predicted cardiovascular risk

June 9, 2011

Source: BMJ, 2011, 342 (7809) p. 1229

Follow this link for the abstract

Date of publication: June 2011

Publication type: News item

In a nutshell: A randomised study of 378 people who took a 12-week treatment of the polypill has led researchers to calculate that long-term use would reduce the risk of coronary heart disease and ischaemic stroke by approximately 60%. Larger trials are now needed to test whether the combination of medicines in a polypill improves patient adherence.

Length of publication: 1 page

Some important notes: You will need an NHS Athens username and password to access this article. Please contact your local NHS library if you cannot access the full text. Follow this link to find your local NHS library.


Statin treatment for primary prevention of vascular disease

April 11, 2011

Source: BMJ, 2011, 342 (7801) p.811

Follow this link for fulltext

Date of publication: April 2011

Publication type: Research

In a nutshell: Cost-effectiveness analysis of daily treatment of low-dose statins for primary prevention of vascular disease based in the Netherlands, including current prices and the cost of non-adherence. Calculations showed that statins for primary prevention did not seem to be cost-effective in populations at low risk of vascular disease. Adherence to statin treatment needs to be improved.

Length of publication: 9 pages

Some important notes: Please contact your local NHS library if you cannot access the full text. Follow this link to find your local NHS library.


The polypill in the prevention of cardiovascular diseases

December 9, 2010

Source: Circulation, 2010, 122 (20) p. 2078-2088

Follow this link for the abstract

Date of publication: November 2010

Publication type: Report

In a nutshell: This report looks at the case for the polypill as primary prevention, either for individuals at high-risk or to lower risk factor levels in entire populations. It also maintains that the polypill may lead to more widespread and cost-effective secondary prevention, but states that it should be considered as part of a comprehensive global strategy to prevent cardiovascular disease.

Length of publication: 11 pages

Some important notes: You will need an NHS Athens username and password to access this article. Please contact your local NHS library if you cannot access the full text. Follow this link to find your local NHS library.


Effect of calcium supplements on risk of myocardial infarction

August 13, 2010

Source: BMJ, 29th July 2010

Follow this link for fulltext

Date of publication: July 2010

Publication type: Research

In a nutshell: 15 trials were analysed which involved patients taking calcium supplements for more than a year. It was found that calcium supplements without co-administered vitamin D were associated with modest increases in cardiovascular disease.

Length of publication: 9 pages

Some important notes: Please contact your local NHS library if you cannot access the full text. Follow this link to find your local NHS library.


Evaluation of a community pharmacy-based intervention for improving patient adherence to antihypertensives

March 10, 2010

Source: BMC Health Services Research, 2010, 10 (34)

Follow this link for fulltext

Date of publication: February, 2010

Publication type: Research

In a nutshell: This study protocol aims to test a package of interventions by community pharmacists to improve patients’ daily adherence to their antihypertensive medications. Fifty-six pharmacies in Australia will take part in the six month trial, after which time changes in patient adherence and persistance will be measured.

Length of publication: 7 pages

Some important notes: Please contact your local NHS library if you cannot access the full text. Follow this link to find your local NHS library.

Acknowledgement: BioMed Central


Prevention of cardiovascular disease: why do we neglect the most potent intervention?

March 10, 2010

Source: Heart, 2010, 96 (4), 261-2

Follow this link for the abstract

Date of publication: February, 2010

Publication type: Commentary

In a nutshell: Physical activity, even when taken up later in life, has been shown to greatly decrease mortality risk. However, it is not a serious prescription option for the primary prevention of cardiovascular disease. The authors argue that prescribing physical activity, not drugs, should be the standard option in cardiovascular disease prevention.

Length of publication: 2 pages

Some important notes: You will need an NHS Athens username and password to access this article. Please contact your local NHS library if you cannot access the full text. Follow this link to find your local NHS library.